Amgen Stock Slips 2.25%, Trailing S&P 500 Amid Hold Rating
AMGN shares underperformed the broader market, though analysts still expect modest EPS and revenue gains in the next earnings report.
Amgen shares fell 2.25% in recent trading, lagging behind the broader S&P 500 as investors weighed the biopharmaceutical giant's near-term outlook. The decline drew attention ahead of the company's upcoming earnings report, where Wall Street is watching closely for signs of momentum.
Despite the single-session pullback, analyst sentiment has edged higher. The Zacks Consensus EPS estimate climbed 0.84% over the past month, reflecting a modest but notable uptick in confidence around Amgen's earnings trajectory. That revision earned the stock a Zacks Rank of #3, signaling a Hold posture among analysts.
Read more Southern Company Stock Rises as Utilities Beat Broader Market →
On the fundamental side, Amgen is projected to post earnings-per-share growth of 0.89% alongside revenue expansion of 3.68% in its forthcoming quarterly report. Those figures suggest steady, if unspectacular, business performance — a portrait of a large-cap healthcare name navigating a competitive landscape without a dramatic catalyst in either direction.
For investors, the combination of a short-term price dip and incrementally improving analyst estimates creates a nuanced picture. The Hold rating implies neither urgency to buy nor a clear reason to sell, leaving Amgen in a wait-and-see posture as the earnings date approaches. Market participants will likely focus on whether actual results can outpace the modest consensus targets.
Continue reading at Yahoo! Finance Canada.
